Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when the Medicines and Healthcare products Regulatory Agency expects to publish its research comparing the risk of meningioma associated with Depo-Provera and other contraceptives.

The Medicines and Healthcare products Regulatory Agency (MHRA) expects to complete its review of the risk of meningioma associated with Depo-Provera and other contraceptives using data from the Clinical Practice Research Datalink in June 2028. The MHRA will seek to publish the findings in peer-reviewed journals once the analysis is complete.